Conmed Corp.
Congress has disclosed 1 buy and 1 sell of CNMD (Conmed Corp.) in official financial disclosures, each linked to its original filing. A transparency record — not investment advice.
Activity Congressional Activity
Fundamentals · FY2026 Valuation
Standard valuation multiples from SEC-reported GAAP financials (trailing twelve months), each compared to the median for —. We use reported GAAP, not forward or adjusted earnings, so our figures can sit higher than sites that do — especially for companies with falling profit. Relative context — not a target price or investment advice.
how it's calculated
how it's calculated
2 trades Recent Congressional Trades
Two things to watch per trade: the disclosure lag (how many days passed before the trade was made public) and the price move in that window (how the stock moved during those non-public days). A sell followed by a price drop, or a buy followed by a rise, means well-timed trading — visible here in the open. Note: the Score measures how notable a trade is, not whether it made money — the price move is shown for context and isn't part of it.
| Politician | Chamber | Type | Owner | Date | Disclosure lag | Price move in that window | Amount | Score | Source |
|---|---|---|---|---|---|---|---|---|---|
| Nicholas Taylor | House | SELL | Spouse | 2019-03-25 | 0 days | — | $1K–$15K | 40.4 | ↗ filing |
| Nicholas Taylor | House | BUY | Spouse | 2019-02-15 | 0 days | — | $1K–$15K | 75.9 | ↗ filing |
Corporate insiders · SEC Form 4 Insider Activity
What the company's own officers and directors did in CNMD — open-market purchases and sales from SEC Form 4 filings (option exercises, grants and tax withholding are excluded). This is context for the congressional activity above, never a buy/sell signal, and the two datasets are kept separate on purpose. Does convergence mean anything? →
Of the congressional trades in CNMD, 0 coincided with corporate insiders moving the same way within 60 days, and 0 with insiders moving the opposite way. This is co-occurrence only — whether it carries any edge is tested honestly on the convergence page.
| Date | Insider | Role | Type | Size | Source |
|---|---|---|---|---|---|
| 2025-11-21 | Glaze Richard | C-suite | SELL 10b5-1 | $11K | ↗ EDGAR |
| 2025-11-06 | Garner Todd W | C-suite | SELL 10b5-1 | $150K | ↗ EDGAR |
| 2025-09-12 | Farkas Charles | Director | SELL | $59K | ↗ EDGAR |
| 2025-09-12 | Farkas Charles | Director | SELL | $48K | ↗ EDGAR |
| 2025-08-07 | Garner Todd W | C-suite | SELL | $31K | ↗ EDGAR |
| 2025-05-05 | Farkas Charles | Director | SELL | $228K | ↗ EDGAR |
| 2025-02-11 | Glaze Richard | C-suite | SELL | $17K | ↗ EDGAR |
| 2024-06-14 | Peters Stanley W III | C-suite | SELL | $287K | ↗ EDGAR |
| 2024-05-13 | BRONSON DAVID M | Director | BUY | $97K | ↗ EDGAR |
| 2024-05-08 | Schwarzentraub Barbara J | Director | BUY | $100K | ↗ EDGAR |
| 2024-05-06 | Aronson Martha Goldberg | Director | BUY | $142K | ↗ EDGAR |
| 2024-04-30 | Beyer Pat | C-suite | BUY | $205K | ↗ EDGAR |
| 2023-12-04 | Peters Stanley W III | C-suite | SELL | $253K | ↗ EDGAR |
| 2023-11-07 | Peters Stanley W III | C-suite | SELL | $123K | ↗ EDGAR |
| 2023-09-13 | Peters Stanley W III | C-suite | SELL | $215K | ↗ EDGAR |
| 2023-08-16 | Garner Todd W | C-suite | SELL | $152K | ↗ EDGAR |
| 2023-06-15 | Hartman Curt R | C-suite | SELL | $136K | ↗ EDGAR |
| 2023-06-08 | Ferrell John D. | Other | SELL | $224K | ↗ EDGAR |
| 2023-06-08 | Peters Stanley W III | Other | SELL | $656K | ↗ EDGAR |
| 2023-06-07 | CONCANNON BRIAN | Director | SELL | $105K | ↗ EDGAR |
| 2023-05-22 | Peters Stanley W III | Other | SELL | $181K | ↗ EDGAR |
| 2023-05-18 | Peters Stanley W III | Other | SELL | $179K | ↗ EDGAR |
| 2023-05-01 | CONCANNON BRIAN | Director | SELL | $259K | ↗ EDGAR |
| 2023-04-28 | Berge Terence M | Other | SELL | $357K | ↗ EDGAR |
| 2023-04-28 | Berge Terence M | Other | SELL | $685K | ↗ EDGAR |
Combined timeline — Congress & insiders
Both sets of trades on one timeline, newest first, so you can see when they lined up. Congress vs ◆ insider.
| Date | Who | Type | Size | |
|---|---|---|---|---|
| ◆ insider | 2025-11-21 | Glaze Richard C-suite 10b5-1 | SELL | $11K |
| ◆ insider | 2025-11-06 | Garner Todd W C-suite 10b5-1 | SELL | $150K |
| ◆ insider | 2025-09-12 | Farkas Charles Director | SELL | $59K |
| ◆ insider | 2025-09-12 | Farkas Charles Director | SELL | $48K |
| ◆ insider | 2025-08-07 | Garner Todd W C-suite | SELL | $31K |
| ◆ insider | 2025-05-05 | Farkas Charles Director | SELL | $228K |
| ◆ insider | 2025-02-11 | Glaze Richard C-suite | SELL | $17K |
| ◆ insider | 2024-06-14 | Peters Stanley W III C-suite | SELL | $287K |
| ◆ insider | 2024-05-13 | BRONSON DAVID M Director | BUY | $97K |
| ◆ insider | 2024-05-08 | Schwarzentraub Barbara J Director | BUY | $100K |
| ◆ insider | 2024-05-06 | Aronson Martha Goldberg Director | BUY | $142K |
| ◆ insider | 2024-04-30 | Beyer Pat C-suite | BUY | $205K |
| ◆ insider | 2023-12-04 | Peters Stanley W III C-suite | SELL | $253K |
| ◆ insider | 2023-11-07 | Peters Stanley W III C-suite | SELL | $123K |
| ◆ insider | 2023-09-13 | Peters Stanley W III C-suite | SELL | $215K |
| ◆ insider | 2023-08-16 | Garner Todd W C-suite | SELL | $152K |
| ◆ insider | 2023-06-15 | Hartman Curt R C-suite | SELL | $136K |
| ◆ insider | 2023-06-08 | Ferrell John D. Other | SELL | $224K |
| ◆ insider | 2023-06-08 | Peters Stanley W III Other | SELL | $656K |
| ◆ insider | 2023-06-07 | CONCANNON BRIAN Director | SELL | $105K |
| ◆ insider | 2023-05-22 | Peters Stanley W III Other | SELL | $181K |
| ◆ insider | 2023-05-18 | Peters Stanley W III Other | SELL | $179K |
| ◆ insider | 2023-05-01 | CONCANNON BRIAN Director | SELL | $259K |
| ◆ insider | 2023-04-28 | Berge Terence M Other | SELL | $357K |
FAQ Common questions
How much has Congress traded CNMD?
1 disclosed buys and 1 sells of CNMD (Conmed Corp.) appear in official congressional financial disclosures.
Is it legal for members of Congress to trade CNMD?
Members of Congress may trade stocks but must disclose it under the STOCK Act. QuantCapitol tracks those public disclosures for transparency — nothing here is an accusation of wrongdoing or investment advice.
Where does this data come from?
Official US House Clerk and Senate electronic financial disclosures. Every trade links back to its original filing so you can verify it yourself.